» Articles » PMID: 7830069

Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 1995 Feb 1
PMID 7830069
Citations 146
Authors
Affiliations
Soon will be listed here.
Abstract

Cholinergic markers, neuropeptides, and amines and their metabolites were sampled from identical specimens across 10 neocortical regions in a large sample of Alzheimer's disease (AD) cases and controls. Levels of choline acetyltransferase, acetylcholinesterase, somatostatin, corticotropin-releasing factor, serotonin, and 5-hydroxyindoleacetic acid were significantly reduced in AD versus controls. After data reduction, the most descriptive neurochemical indices were used to examine the relationship of neurochemical measures and dementia severity within the AD sample, controlling for age effects. Dementia severity ratings were based on antemortem assessments (46.9% of AD sample) and postmortem chart review (53.1% of the AD sample). Choline acetyltransferase activity was highly correlated with clinical dementia ratings across the neocortex of the AD cases. Somatostatin and corticotropin-releasing factor levels were correlated with dementia severity only when control cases were included in the analyses. None of the amines, their metabolites, or the neuropeptides quantified related significantly to dementia severity in the AD cohort. These data (a) confirm the strong association of cholinergic deficits with functional impairment in AD and show that this association is independent of age and (b) suggest that of all the neurochemical species quantified, the cholinergic indices may be unique in their association with dementia severity.

Citing Articles

Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer's disease: long-term follow up.

Knezovic A, Salkovic-Petrisic M J Neural Transm (Vienna). 2025; .

PMID: 39891708 DOI: 10.1007/s00702-025-02887-2.


Deprescribing anticholinergics to preserve brain health: reducing the risk of dementia through deprescribing (R2D2): study protocol for a randomized clinical trial.

Campbell N, Holden R, Gao S, Unverzagt F, Lane K, Carter A Trials. 2024; 25(1):788.

PMID: 39578926 PMC: 11583418. DOI: 10.1186/s13063-024-08618-4.


Deprescribing Anticholinergics to Preserve Brain Health: Reducing the Risk of Dementia through Deprescribing (R2D2): Study Protocol for a Randomized Clinical Trial.

Campbell N, Holden R, Gao S, Unverzagt F, Lane K, Carter A Res Sq. 2024; .

PMID: 39574889 PMC: 11581051. DOI: 10.21203/rs.3.rs-4682599/v1.


Heterologous expressing melittin in a probiotic yeast to evaluate its function for promoting NSC-34 regeneration.

Huang H, Hsu H, Kuo C, Wu M, Lai C, Chang G Appl Microbiol Biotechnol. 2024; 108(1):496.

PMID: 39466458 PMC: 11519230. DOI: 10.1007/s00253-024-13336-7.


Human Alzheimer's Disease ATN/ABC Staging Applied to Aging Rhesus Macaque Brains: Association With Cognition and MRI-Based Regional Gray Matter Volume.

Barnes C, Permenter M, Vogt J, Chen K, Beach T J Comp Neurol. 2024; 532(9):e25670.

PMID: 39315417 PMC: 11451939. DOI: 10.1002/cne.25670.